ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0754

Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients

Milena Bond1, Philipp Bosch2, Aaron Juche3, Hans Bastian3 and Wolfgang Schmidt4, 1South Tyrol Health Trust and Teaching Hospital of the Paracelsus Medical University, Brunico, Italy, 2Medical University of Graz, Graz, Austria, 3Rheumaklinik Berlin-Buch, Berlin, Germany, 4Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany

Meeting: ACR Convergence 2025

Keywords: Environmental factors, Epidemiology, giant cell arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Whether the disease onset in giant cell arteritis (GCA) exhibits a seasonal pattern remains unclear. Previous studies have yielded conflicting evidence: some report no seasonality, while others suggest seasonal variation, though findings are inconsistent and difficult to compare, especially due to methodological limitations, including small cohort sizes and reliance on diagnosis or biopsy dates rather than symptoms onset. We aimed to clarify whether a seasonal pattern exists by analyzing a large cohort using the date of symptom onset as the temporal reference.

Methods: Consecutive patients from a large German monocentric GCA cohort in Berlin-Buch (1994–2024) with a documented date of symptom onset were included. To ensure balanced seasonal representation, patients with symptom onset outside the period of December 1, 1994, to November 30, 2023, were excluded. Meteorological seasons were used for the analysis (spring: Mar–May; summer: Jun–Aug; autumn: Sep–Nov; winter: Dec–Feb). To assess whether symptom onsets were equally distributed across seasons (25% per season), we applied an exact multinomial test using the “ExactMultinom” package in R. Sensitivity analyses were performed for subgroups by sex and clinical phenotype (cranial vs extracranial involvement), with Bonferroni-Holm correction for multiple testing.

Results: Of 1203 patients in the full cohort, 1149 fulfilled the inclusion criteria and were included in the main analysis (population’s characteristics are reported in Table 1). The overall seasonal distribution of symptom onset was: spring 292 (25.4%), summer 276 (24.0%), autumn 271 (23.6%), winter 310 (27.0%) (p = 0.36). Figure 1 illustrates the seasonal distribution of symptom onset stratified by years across the study period. Subgroup analyses revealed no overall significant seasonal variation as shown in Table 2.

Conclusion: This large, single-center cohort study using symptom onset data found no evidence of a significant seasonal pattern in the disease onset of GCA patients.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. Bond: AbbVie/Abbott, 6; P. Bosch: AbbVie/Abbott, 1, 6, Eli Lilly, 6, Novartis, 6, Pfizer, 5, UCB, 6; A. Juche: AbbVie/Abbott, Novartis, 12, participated in trials as investigator; H. Bastian: Alfasigma, 12, Congress and travel expenses, Celltrion, 12, Congress and travel expenses, Novartis, 5, 12, Congress and travel expenses; W. Schmidt: AbbVie, 1, 5, 6, Alfasigma, 6, Amgen, 6, Boehringer-Ingelheim, 1, Chugai, 6, Eli Lilly, 6, Fresenius Kabi, 1, GlaxoSmithKline, 6, Medac, 6, Novartis, 1, 5, 6, Pfizer, 6, UCB, 6.

To cite this abstract in AMA style:

Bond M, Bosch P, Juche A, Bastian H, Schmidt W. Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/is-there-a-seasonal-pattern-in-giant-cell-arteritis-revisiting-the-evidence-in-a-large-monocentric-cohort-of-1203-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-there-a-seasonal-pattern-in-giant-cell-arteritis-revisiting-the-evidence-in-a-large-monocentric-cohort-of-1203-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology